The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Danish obesity drug giant Novo Nordisk is set ...

By Mrinalika Roy and Siddhi Mahatole Feb 3 (Reuters) - Shares of obesity drugmakers and developers slid on Tuesday, after ...

The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is ...

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

Obesity is contributing to a record proportion of deaths among pregnant women, the Royal College of Physicians has warned.

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Meanwhile, the U.K.'s Medicines and Healthcare Products Regulatory Agency updated its warnings on GLP-1 and dual GLP-1/GIP ...

Researchers reviewed the body mass index of over 11 million Americans.

Lilly CEO Dave Ricks is confident in the ability of the company's pill to compete and is preparing for a "full launch" in the second quarter.

The prevalence of obese adults in the United States more than doubled between 1990 and 2022.

Global pharmaceutical company Pfizer (NYSE:PFE) beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 1.2% ...